



Choose the right genomic test for a clear path forward

The Oncotype DX Genomic Prostate Score® (GPS™) assay helps guide the key decision between Active Surveillance and immediate treatment.

Metastasis and death are rare events in the Active Surveillance population¹⁻⁴

Adverse pathology (AP) is the most actionable endpoint to inform management of Gleason 3+3 and 3+4 patients. The GPS assay predicts AP to help you determine which patients are candidates for Active Surveillance and which may benefit from immediate treatment.⁵

Focus on AP for critical treatment decisions

Expected outcomes for patients with clinically low-risk biopsy at RP⁶⁻¹¹



Patients with AP have ~50% risk of clinical progression

The GPS assay was validated for clinically low- and favorable intermediate-risk prostate cancer using the strongest definition of AP: the presence of high-grade and/or non-organ-confined disease.^{†12}

*Gleason \leq 3+4 and <pT3.

[†]Gleason \geq 4+3 and/or \geq pT3.

BCR = biochemical recurrence; PCM = prostate cancer mortality; RP = radical prostatectomy.

GPS and Oncotype DX Genomic Prostate Score are trademarks of Genomic Health Inc., an Exact Sciences corporation. Exact Sciences is a registered trademark of Exact Sciences corporation. ©2020 Genomic Health Inc., an Exact Sciences corporation. All rights reserved. EXS40381_0620

The only assay designed for critical treatment decisions in clinically low-risk, early-stage prostate cancer

Comparison of prostate biopsy genomic tests

	Oncotype DX GPS assay	Prolaris® Test	Decipher® Prostate Biopsy Test
Genes selected based on their performance in prostate cancer in the biopsy setting ¹³⁻¹⁶	✓	—	—
Extensively validated across large cohorts of GS 3+3 and 3+4 patients who are eligible for Active Surveillance ^{13,16-31}	✓	—	—
Optimized and analytically validated for small prostate biopsy tissue samples ^{14,22,32}	✓ 5 ng of RNA	200 ng RNA	25-100 ng of RNA

Validated endpoints in a biopsy setting:

Oncotype DX GPS assay	Prolaris® Test	Decipher® Prostate Biopsy Test
<ul style="list-style-type: none"> • Metastasis after RP²⁵ • PCM after RP²⁵ • AP (Gleason grade $\geq 4+3$ and/or pT3+)^{13*} • BCR^{19,25} 	<ul style="list-style-type: none"> • Metastasis after RP³³ • PCM after conservative management (watchful waiting)^{28,29} • BCR³³ 	<ul style="list-style-type: none"> • Metastasis after RP¹⁵ • PCM after RP¹⁵ • AP (Gleason $\geq 4+3$ and pT3b+ only)³⁰

Choose the Oncotype DX GPS assay to drive immediate and actionable treatment decisions.

Contact your local Exact Sciences representative or call **866 ONCOTYPE (866-662-6897)**.

RP = radical prostatectomy; BCR = biochemical recurrence; PCM = prostate cancer mortality.

*Prospective validation data for this clinical endpoint.²¹

References: 1. Musunuru et al. *J Urol*. 2016. 2. Hamdy et al. *NEJM*. 2016. 3. Tosoian. *J Clin Oncol*. 2015. 4. Tosoian et al. *Eur Urol*. 2020. 5. Brand et al. *Urology*. 2016. 6. Epstein et al. *Eur Urol*. 2016. 7. Eggener et al. *J Urol*. 2011. 8. Dinh et al. *J Urol*. 2015. 9. Cooperberg et al. *Cancer*. 2011. 10. Tilki et al. *J Urol*. 2015. 11. Tosoian et al. *J Urol*. 2013. 12. Kozminski et al. *Urol Oncol*. 2016. 13. Klein et al. *Eur Urol*. 2014. 14. Cuzick et al. *Lancet Oncol*. 2011. 15. Nguyen et al. *Eur Urol*. 2017. 16. Erho et al. *PLoS ONE*. 2013. 17. Badani et al. *Urol Pract*. 2015. 18. Bonham et al. *USCAP*. 2016. 19. Cullen et al. *Eur Urol*. 2015. 20. Dall'Era et al. *Urol Pract*. 2015. 21. Eggener et al. *Urology*. 2019. 22. Knezevic et al. *BMC Genomics*. 2013. 23. Lynch et al. *Am J Manag Care*. 2018. 24. Salmasi et al. *J Urol*. 2018. 25. Van Den Eeden et al. *Eur Urol*. 2017. 26. Eure et al. *Urology*. 2017. 27. Eure et al. *AUA*. 2017. 28. Cuzick et al. *Br J Cancer*. 2015. 29. Cuzick et al. *Br J Cancer*. 2012. 30. Kim et al. *Prostate Cancer Prostatic Dis*. 2018. 31. Albala et al. *Rev Urol*. 2016. 32. Klein et al. *Urol*. 2016. 33. Bishoff et al. *J Urol*. 2014.

GPS, Oncotype DX, and Oncotype DX Genomic Prostate Score are trademarks of Genomic Health Inc., an Exact Sciences corporation. Exact Sciences is a registered trademark of Exact Sciences corporation.

©2020 Genomic Health Inc., an Exact Sciences corporation. All rights reserved. EXS40381_0620



oncotypeDX®
Genomic Prostate Score